Dr. Matthew B. Klein is the CEO of PTC Therapeutics, where he took the helm in March 2023 after joining the company in 2019. Before becoming CEO, he held various leadership roles, including Chief Operating Officer and Chief Development Officer....

Dr. Matthew B. Klein is the CEO of PTC Therapeutics, where he took the helm in March 2023 after joining the company in 2019. Before becoming CEO, he held various leadership roles, including Chief Operating Officer and Chief Development Officer. His educational background is impressive: he has a BA from the University of Pennsylvania, an MD from Yale, and an MS in Epidemiology from the University of Washington. Dr. Klein's career has included significant roles at BioElectron, where he was the CEO and Chief Medical Officer before he joined PTC. Under his leadership, PTC Therapeutics is focusing on the development of innovative treatments, leveraging his extensive experience in clinical development and regulatory strategies. Interestingly, in 2023, his total compensation reached about $8.94 million, which reflects his position and the responsibilities he handles. The structure of his pay is aligned with the company’s performance, ensuring that he is invested in the firm's success. Dr. Klein is also involved on the board of ClearPoint Neuro, enriching his experience in the biotech field as he guides PTC to new heights in therapeutic solutions.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other PTC Therapeutics CEOs

P

Dr. Matthew B. Klein

CEO of PTC Therapeutics

Education

BA from the University of Pennsylvania, MD from Yale University School of Medicine, MS in Epidemiology from the University of Washington School of Public Health

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1972 - 53 years ago

CEO of PTC Therapeutics for

2 years 1 month (Mar 2023 - Present)

Previous Experience

Chief Operating Officer at PTC Therapeutics, Inc.; formerly CEO of BioElectron Technology Corporation.

Rivals

Competitors/colleagues of Dr. Matthew B. Klein

Holdings

See how much did Dr. Matthew B. Klein make over time.

Dr. Klein has a noteworthy stake in PTC Therapeutics, reflecting his commitment to the company. Following his promotion to CEO in March 2023, he received significant equity awards that include 130,000 stock options and 127,000 restricted stock units. His holdings...

Dr. Klein has a noteworthy stake in PTC Therapeutics, reflecting his commitment to the company. Following his promotion to CEO in March 2023, he received significant equity awards that include 130,000 stock options and 127,000 restricted stock units. His holdings peaked when he transitioned to this CEO role and continued to grow due to various grants linked to performance milestones. His insider ownership level indicates his strong belief in PTC's future, as he has previously held positions where he made strategic decisions that positively affected company performance and stock value. As of the latest reports, he holds shares that demonstrate both his confidence in PTC's direction and his long-term investment in the company’s success.

Total Stock Sold

$2.62M

PTCT

$2.62M

59,595 PTCT shares

What if they kept their stock?

If Dr. Matthew B. Klein didn't sell their stock, today they would have:
Extra PTCT59,595 shares worth $2.65M.
This is 1.25% and $32.68K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Matthew B. Klein.

PTCT

$390.46K

PTCT at $50.11/share

Feb 19, 2025

Sale

PTCT

$204.12K

PTCT at $44.92/share

Jan 7, 2025

Sale

PTCT

70,000 shares

PTCT

Jan 3, 2025

Received

PTCT

$373.88K

PTCT at $45.16/share

Dec 31, 2024

Sale

PTCT

$83.67K

PTCT at $24.89/share

Apr 19, 2024

Sale

PTCT

$32.85K

PTCT at $25.14/share

Apr 17, 2024

Sale

PTCT

70,000 shares

PTCT

Feb 15, 2024

Received

PTCT

$221.40K

PTCT at $28.83/share

Jan 8, 2024

Sale

PTCT

$274.39K

PTCT at $27.15/share

Jan 5, 2024

Sale

PTCT

75,000 shares

PTCT

Dec 28, 2023

Received

Compensation History

See how much did Dr. Matthew B. Klein make over time.

In 2023, Dr. Klein's total compensation package was approximately $8.94 million, structured to align with the performance of PTC Therapeutics and to reflect the responsibilities of his role. His salary was about $747,222, significantly increasing when he became CEO. Dr. Klein didn’t receive bonuses this year as the company’s performance was slightly below target, reflecting a solid executive incentive culture that ties pay to measurable outcomes. In terms of equity, he was awarded 65,000 stock options and 26,000 restricted stock units at the time of his promotion, which are designed to reward him for long-term performance and retention at the firm. Overall, his compensation structure illustrates a commitment not just to personal financial gain, but also to the company's growth as his wealth is closely tied to its success.

Year

2023

Total Compensation

$1.22M

Salary

$747.22K

Board Justification

The compensation philosophy is to align executive compensation with company performance and shareholder interests, with a significant portion being 'at risk'.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023 as the corporate rating was 80% of target and individual performance modifier was 1.0, resulting in a cash incentive of $472,800 based on corporate performance.

Other

$472.80K

Board Justification

Includes the cash awards earned under the annual incentive program based on corporate performance.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the stock options and RSUs granted in 2023 have not yet vested.

Performance Metrics

The performance metrics for 2023 included achieving corporate goals related to financial performance, commercial success, advancing programs and pipelines, and operational excellence.

Other PTC Therapeutics CEOs

Here are other CEOs of PTC Therapeutics

Dr. Stuart W. Peltz

Founder and Ex-CEO of PTC Therapeutics

January 2013 - March 2023